Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.
BioMark Diagnostics Inc. develops liquid biopsy technologies for early cancer detection, with news centered on metabolomic profiling, machine learning models, and lung cancer screening applications. Company updates commonly cover clinical research collaborations, peer-reviewed validation work, respiratory medicine forums, and efforts to apply biomarker testing alongside established screening pathways.
BioMark news also includes intellectual property developments for its metabolic liquid biopsy platform, recognition of collaborative lung cancer screening projects, governance appointments, and commercialization-related activity tied to laboratory standards, distribution channels, and market access for oncology diagnostics.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a developer of liquid biopsy tests for early cancer detection, will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. CEO Rashid Bux and CSO Jean-François Haince will showcase BioMark's pipeline of liquid biopsy tests for lung cancer, breast cancer, and glioblastoma.
The company's presentation will be available on-demand through the conference portal on September 9, 2024, at 7:00 a.m. Eastern Time. BioMark will also conduct one-on-one meetings virtually. This event provides an opportunity for BioMark to connect with potential investors, partners, and industry experts as they prepare for the commercial launch of their early lung cancer assay and U.S. market entry.
BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTC Pink: BMKDF) has been granted U.S. Patent No. 17/895.69 by the USPTO, strengthening its liquid biopsy technology for cancer management. The patent protects BioMark's SAT1 legacy assay platform for assessing tumor velocity and treatment response in glioblastoma (GBM) and triple-negative breast cancer (TNBC) patients with specific genetic mutations.
Key points:
- GBM market size estimated at $2.80 billion in 2024, expected to reach $4.60 billion by 2029 (CAGR 8%)
- TNBC accounts for 15% of all breast cancers
- BioMark plans to launch a preclinical study for TNBC patients with BRCA mutations
- The patent enhances BioMark's position in developing cancer management solutions
BioMark Diagnostics Inc. (CSE: BUX) (OTC Pink: BMKDF) announced that collaborators from the University of Manitoba will present new research findings on glioblastoma at the 2024 GPEN Conference in Copenhagen. The presentations focus on:
1. Evaluation of hydrogel formulations for delivering siRNA to glioblastoma tumor cells
2. Examination of potential drug biomarker candidates for glioblastoma
The research highlights BioMark's liquid biopsy technology for evaluating minimal residual disease and treatment outcomes in glioblastoma. CEO Rashid Ahmed Bux emphasized their comprehensive approach, including biomarker discovery, novel drug delivery mechanisms, and potential gene knockdown treatments for glioblastoma.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.